{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T12:36:49Z","timestamp":1760099809071},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2006,3,1]],"date-time":"2006-03-01T00:00:00Z","timestamp":1141171200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hautarzt"],"published-print":{"date-parts":[[2006,3]]},"DOI":"10.1007\/s00105-006-1104-0","type":"journal-article","created":{"date-parts":[[2006,2,24]],"date-time":"2006-02-24T13:42:41Z","timestamp":1140788561000},"page":"185-194","source":"Crossref","is-referenced-by-count":13,"title":["Behandlung der toxischen epidermalen Nekrolyse"],"prefix":"10.1007","volume":"57","author":[{"given":"P.","family":"Spornraft-Ragaller","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Theilen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G. S.","family":"Gottschlich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Ragaller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"1104_CR1","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1001\/archderm.139.1.33","volume":"139","author":"Bachot","year":"2003","unstructured":"Bachot N, Revuz J, Roujeau JC (2003) Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis: a prospective noncomparative study showing no benefit on mortality or progression. Arch Dermatol 139(1):33\u201336","journal-title":"Arch Dermatol"},{"key":"1104_CR2","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1046\/j.1523-1747.2000.00061.x","volume":"115","author":"Bastuji-Garin","year":"2000","unstructured":"Bastuji-Garin S, Fouchard N, Bertocchi M et al. (2000) SCORTEN: a severity -of illness score for toxic epidermal necrolysis. J Invest Dermatol 115:149\u2013153","journal-title":"J Invest Dermatol"},{"key":"1104_CR3","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1001\/archderm.1993.01680220104023","volume":"129","author":"Bastuji-Garin","year":"1993","unstructured":"Bastuji-Garin S, Rzany B, Stern RS et al. (1993) Clinical classification of cases of toxic epidermal necrolysis, Stevens Johnson Syndrome and erythema multiforme. Arch Dermatol 129:92\u201396","journal-title":"Arch Dermatol"},{"key":"1104_CR4","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/01.BCR.0000105096.93526.27","volume":"25","author":"Brown","year":"2004","unstructured":"Brown KM, Silver GM, Halerz M et al. (2004) Toxic epidermal necrolysis: does immunoglobulin make a difference? J Burn Care Rehabil 25(1):81\u201388","journal-title":"J Burn Care Rehabil"},{"key":"1104_CR5","first-page":"430","volume":"83","author":"Campione","year":"2003","unstructured":"Campione E, Marulli GC, Carrozzo AM et al. (2003) High-dose intravenous immunoglobulin for severe drug reactions: efficacy in toxic epidermal necrolysis. Acta Derm Venereol 83(6):430\u2013432","journal-title":"Acta Derm Venereol"},{"key":"1104_CR6","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/428486a","volume":"428","author":"Chung","year":"2004","unstructured":"Chung WH, Hung SI, Hong HS et al. (2004) Medical genetics: a marker for Stevens-Johnson syndrome. Nature 428(6982):486","journal-title":"Nature"},{"key":"1104_CR7","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1001\/archderm.1993.01680250078010","volume":"129","author":"Correia","year":"1993","unstructured":"Correia O, Delgado L, Ramos JP et al. (1993) Cutaneous T-cell recruitment in toxic epidermal necrolysis: further evidence CD8 lymphocyte invovement. Arch Dermatol 129:466\u2013468","journal-title":"Arch Dermatol"},{"key":"1104_CR8","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1001\/archderm.136.3.323","volume":"136","author":"Garcia-Doval","year":"2000","unstructured":"Garcia-Doval I, LeCleach L, Bocquet H et al. (2000) Toxic epidermal necrolysis and Stevens-Johnson syndrome. Does early withdrawal of causative drugs decrease the risk of death? Arch Dermatol 136:323\u2013411","journal-title":"Arch Dermatol"},{"key":"1104_CR9","doi-asserted-by":"crossref","first-page":"5","DOI":"10.5070\/D397D8T291","volume":"8","author":"Ghislain","year":"2002","unstructured":"Ghislain PD, Roujeau JC (2002) Treatment of severe drug reactions: Stevens-Johnson syndrome, toxic epidermal necrolysis and hypersensitivity syndrome. Dermatol Online J 8(1):5","journal-title":"Dermatol Online J"},{"key":"1104_CR10","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1001\/archderm.1995.01690180043007","volume":"131","author":"Guibal","year":"1995","unstructured":"Guibal F, Bastuji-Garin S, Chosidow O et al. (1995) Characteristics of toxic epidermal necrolysis in patients undergoing long-term glucocorticoid therapy. Arch Dermatol 131:669\u2013672","journal-title":"Arch Dermatol"},{"key":"1104_CR11","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1097\/00000658-198611000-00001","volume":"204","author":"Halebian","year":"1986","unstructured":"Halebian PH, Madden MR, Finklestein J et al. (1986) Improved burn center survival of patients with toxic epidermal necrolysis managed without corticosteroids. Ann Surg 204:503\u2013512","journal-title":"Ann Surg"},{"key":"1104_CR12","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1007\/s00101-002-0404-8","volume":"51","author":"J\u00e4ckel","year":"2002","unstructured":"J\u00e4ckel R, Fuchs M, Raff T, Wiedemann B (2002) Arzneimittelbedingte toxisch epidermale Nekrolyse mit Beteiligung des Intestinal- und Respirationstraktes. Anaesthesist 51:815\u2013819","journal-title":"Anaesthesist"},{"key":"1104_CR13","doi-asserted-by":"crossref","first-page":"2957","DOI":"10.1001\/jama.1993.03510240069035","volume":"270","author":"Le Gall","year":"1993","unstructured":"Le Gall R, Lemenshow S, Saulnier F (1993) A new simplified acute physiology score (SAPS II) based on a European\/North american multicenter study. JAMA 270:2957\u20132963","journal-title":"JAMA"},{"key":"1104_CR14","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/j.1365-2133.1956.tb12766.x","volume":"68","author":"Lyell","year":"1956","unstructured":"Lyell A (1956) Toxic epidermal necrolysis: an eruption resembling scalding of the skin. Br J Dermatol 68:355\u2013361","journal-title":"Br J Dermatol"},{"key":"1104_CR15","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1159\/000070938","volume":"207","author":"Magina","year":"2003","unstructured":"Magina S, Lisboa C, Leal V et al. (2003) Dermatological and opthalmological sequels in toxic epidermal necrolysis. Dermatology 207(1):33\u201336","journal-title":"Dermatology"},{"key":"1104_CR16","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1097\/00006534-199809020-00014","volume":"102","author":"McGee","year":"1998","unstructured":"McGee T, Munster A (1998) Toxic epidermal necrolysis syndrome: mortality rate reduced with early referral to regional burn center. Plast Reconstr Surg 102:1018\u20131022","journal-title":"Plast Reconstr Surg"},{"key":"1104_CR17","doi-asserted-by":"crossref","unstructured":"Mockenhaupt M, Norgauer J (2002) Cutaneous adverse drug reactions. Stevens-Johnson syndrome and toxic epidermal necrolysis. ACI International 14\/4:143\u2013150","DOI":"10.1027\/0838-1925.14.4.143"},{"key":"1104_CR18","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/00004630-200203000-00004","volume":"23","author":"Palmieri","year":"2002","unstructured":"Palmieri TL, Greenhalgh DG, Saffle JR et al. (2002) A multicenter review of toxic epidermal necrolysis treated in U.S. burn centers at the end of the twentieth century. J Burn Care Rehabil 23(2):87\u201396","journal-title":"J Burn Care Rehabil"},{"key":"1104_CR19","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1159\/000083947","volume":"136","author":"Paquet","year":"2005","unstructured":"Paquet P, Pierard GE, Quatresooz P (2005) Novel treatments for drug-induced toxic epidermal necrolysis (Lyell\u201as syndrome). Int Arch Allergy Appl Immunol 136(3):205\u2013216","journal-title":"Int Arch Allergy Appl Immunol"},{"key":"1104_CR20","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1001\/archderm.139.1.26","volume":"139","author":"Prins","year":"2003","unstructured":"Prins C, Kerdel FA, Padilla RS et al. (2003) Treatment of toxic epidermal necrolysis with high-dose intravenous immunoglobulins: multicenter retrospective analysis of 48 consecutive cases. Arch Dermatol 139(1):26\u201332","journal-title":"Arch Dermatol"},{"key":"1104_CR21","first-page":"Electronic","volume":"Type","author":"Reinhart","year":"2005","unstructured":"Reinhart K et al. (2005) S2-Leitlinien der Deutschen Sepsis-Gesellschaft e.V. und der DIVI. Diagnose und Therapie der Sepsis. http:\/\/www.awmf-online.de. Ref Type: Electronic Citation","journal-title":"Ref"},{"key":"1104_CR22","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1080\/000155599750010689","volume":"79","author":"Rhodes","year":"1999","unstructured":"Rhodes LE, Hashim IA, McLaughlin PJ, Friedmann PS (1999) Blister fluid cytokines in cutaneous inflammatory bullous disorders. Acta Derm Venereol 79(4):288\u2013290","journal-title":"Acta Derm Venereol"},{"key":"1104_CR23","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1159\/000233856","volume":"78","author":"Roujeau","year":"1985","unstructured":"Roujeau JC, Albengres E, Moritz S et al. (1985) Lymphocyte transformation test in drug- induced toxic epidermal nekrolysis. Int Arch Allergy Appl Immunol 78(1):22\u201324","journal-title":"Int Arch Allergy Appl Immunol"},{"key":"1104_CR24","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/0190-9622(90)70333-D","volume":"23","author":"Roujeau","year":"1990","unstructured":"Roujeau JC, Chosidow O, Saiag P, Guillaume JC (1990) Toxic epidermal necrolysis (Lyell syndrome). J Am Acad Dermatol 23(6):1039\u20131058","journal-title":"J Am Acad Dermatol"},{"key":"1104_CR25","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1056\/NEJM199512143332404","volume":"333","author":"Roujeau","year":"1995","unstructured":"Roujeau JC, Kelly JP, Naldi L et al. (1995) Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal nekrolysis. N Engl J Med 333:1600\u20131607","journal-title":"N Engl J Med"},{"key":"1104_CR26","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/j.1365-2133.1996.tb03598.x","volume":"135","author":"Rzany","year":"1996","unstructured":"Rzany B, Hering O, Mockenhaupt M et al. (1996) Histopathological and epidemiological characteristics of patients with erythema exsudativum multiforme major, Stevens-Johnson syndrome and toxic epidermal necrolysis. Br J Dermatol 135:6\u201311","journal-title":"Br J Dermatol"},{"key":"1104_CR27","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/0895-4356(96)00035-2","volume":"49","author":"Rzany","year":"1996","unstructured":"Rzany B, Mockenhaupt M, Baur S et al. (1996) Epidemiology of erythema exsudativum multiforme majus, Stevens-Johnson syndrome, and toxic epidermal nekrolysis in Germany (1990\u20131992): structure and results of a population based registry. J Clin Epidemiol 49(7):769\u2013773","journal-title":"J Clin Epidemiol"},{"key":"1104_CR28","doi-asserted-by":"crossref","unstructured":"Sch\u00f6pf E, Rzany B, Mockenhaupt M (1995) Schwere arzneimittelinduzierte Hautreaktionen: Pemphigus vulgaris, Bull\u00f6ses Pephigoid, generalized bulous fixed drug eruption, Erythema exsudativum multiforme majus, Stevens Johnson Syndrom und Toxisch epidermale Nekrolyse. In: Plewig G, Korting HC (Hrsg) Fortschritte der praktischen Dermatologie und Venerologie. Springer, Berlin Heidelberg New York Tokyo, S 89\u201395","DOI":"10.1007\/978-3-642-79156-7_14"},{"key":"1104_CR29","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1097\/01.BCR.0000124746.33279.86","volume":"25","author":"Shortt","year":"2004","unstructured":"Shortt R, Gomez M, Mittmann N, Cartotto R (2004) Intravenous immunoglobulin does not improve outcome in toxic epidermal necrolysis. J Burn Care Rehabil 25(3):246\u2013255","journal-title":"J Burn Care Rehabil"},{"key":"1104_CR30","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1159\/000051702","volume":"203","author":"Stella","year":"2001","unstructured":"Stella M, Cassano P, Bollero D et al. (2001) Toxic epidermal necrolysis treated with intravenous high-dose immunoglobulins: our experience. Dermatology 203:45\u201349","journal-title":"Dermatology"},{"key":"1104_CR31","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1001\/archderm.139.1.39","volume":"139","author":"Trent","year":"2006","unstructured":"Trent JT, Kirsner RS, Romanelli P, Kerdel FA (2006) Analysis of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis using SCORTEN: The University of Miami experience. Arch Dermatol 139(1):39\u201343","journal-title":"Arch Dermatol"},{"key":"1104_CR32","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1126\/science.282.5388.490","volume":"282","author":"Viard","year":"1998","unstructured":"Viard I, Wehrli P, Bullani R et al. (1998) Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobuline. Science 282:490\u2013493","journal-title":"Science"},{"key":"1104_CR33","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/j.1600-0536.1996.tb02364.x","volume":"35","author":"Wolkenstein","year":"1996","unstructured":"Wolkenstein P, Chosidow O, Flechet ML et al. (1996) Patch testing in severe cutaneous adverse drug reactions, including Stevens-Johnson syndrome and toxic epidermal nekrolysis. Contact Dermatitis 35(4):234\u2013236","journal-title":"Contact Dermatitis"}],"container-title":["Der Hautarzt"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-006-1104-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00105-006-1104-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-006-1104-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,24]],"date-time":"2021-07-24T08:31:44Z","timestamp":1627115504000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00105-006-1104-0"}},"subtitle":["Erfahrungen bei 9\u00a0Patienten unter Ber\u00fccksichtigung von intraven\u00f6sen Immunglobulinen"],"short-title":[],"issued":{"date-parts":[[2006,3]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2006,3]]}},"alternative-id":["1104"],"URL":"https:\/\/doi.org\/10.1007\/s00105-006-1104-0","relation":{},"ISSN":["0017-8470","1432-1173"],"issn-type":[{"value":"0017-8470","type":"print"},{"value":"1432-1173","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,3]]}}}